![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif)
| Sustancia en estudio para el tratamiento de algunos tipos de cáncer. AZD2171 impide la formación de nuevos vasos sanguíneos que los tumores necesitan para crecer y puede destruir las células cancerosas. Es un tipo de inhibidor de la angiogénesis y un tipo de inhibidor de la tirosina cinasa del factor de crecimiento endotelial vascular (FCEV). También se llama cediranib y Recentin. |
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081011024535im_/http://www.nci.nih.gov/images/spacer.gif) |